Deregulated expression or aberrant increased activity of EphA4 is reported in various human diseases such as Alzheimer’s disease (AD), amyotrophic lateral sclerosis, and cancers including breast cancer and pancreatic cancer, suggesting that EphA4 may be a promising drug target6–9. This evidence concerns the gene EPHA4 and familial pancreatic carcinoma.